Omnicell, Inc. v. Medacist Solutions Group, LLC

272 F.R.D. 469, 2011 U.S. Dist. LEXIS 13188, 2011 WL 588072
CourtDistrict Court, N.D. California
DecidedFebruary 10, 2011
DocketNo. 10-CV-04746-LHK
StatusPublished
Cited by6 cases

This text of 272 F.R.D. 469 (Omnicell, Inc. v. Medacist Solutions Group, LLC) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Omnicell, Inc. v. Medacist Solutions Group, LLC, 272 F.R.D. 469, 2011 U.S. Dist. LEXIS 13188, 2011 WL 588072 (N.D. Cal. 2011).

Opinion

ORDER GRANTING MOTION TO DISMISS

LUCY H. KOH, District Judge.

Defendant Medacist Solutions Group, LLC moves to dismiss, or, in the alternative, to transfer this case to the District of Connecticut, pursuant to Federal Rule 12(b)(3) and 28 U.S.C. § 1406(a). Plaintiffs Omnicell, Inc., and Pandora Data Systems, Inc., contend that venue in this District is proper and oppose the motion. The Court heard oral argument on February 3, 2011. Having considered the arguments and submissions of the parties, the Court grants Defendant’s motion to dismiss, without prejudice to Plaintiffs refiling in the appropriate forum.

I. Background

On May 2, 2007, Medacist Solutions Group, LLC (“Medacist”) filed a Complaint against Pandora Data Systems, Inc. (“Pandora”) in the District of Connecticut alleging infringement of U.S. Patent No. 6,842,736 (the “'736 Patent”). See Compl., Medacist Solutions Group, LLC v. Pandora Data Systems, Inc., No. 3:07-cv-692-JCH (D.Conn. May 2, 2007). The parties refer to this action as the Pandora Litigation. On October 20, 2008, Medacist and Pandora entered into a settlement and license agreement (the “Pandora License”) that resolved the Pandora Litigation and granted Pandora certain rights associated with the '736 Patent. Under its terms, the settlement agreement is to be construed, governed, interpreted, and applied in accordance with Connecticut law. Of particular importance to this motion, the settlement agreement provides as follows:

Concurrently with the execution of this Agreement, Medacist and Pandora shall execute and file a Stipulated Request for Dismissal of the Action with prejudice pursuant to F.R.C.P. Rule 41(a). This Dismissal shall provide that each party shall bear its own costs and that the Court will retain jurisdiction to enforce the Agreement.

Deck of Kenneth S. Chang in Supp. of Omni-cell, Inc.’s Response to Medacist Solutions Group, LLC’s Mot. to Dismiss or for Change of Venue (“Chang Deck”), Ex. B § 6.1.

In accordance with this provision, Medacist and Pandora filed a Stipulation of Dismissal, which the District of Connecticut signed and entered on October 29, 2008. Deck of Elizabeth M. Smith in Supp. of Def. Medacist Solutions Group, LLC’s Mot. to Dismiss or for Change of Venue (“Smith Deck”), Ex. A. The Stipulation of Dismissal entered by the District of Connecticut provides in pertinent part:

The Court shall retain jurisdiction, pursuant to Kokkonen v. Guardian Life Ins. Co. of America, 511 U.S. 375, 114 S.Ct. 1673, 128 L.Ed.2d 391 (1994) and the inherent authority of the Court to enforce its orders, over Medacist and Pandora and the subject matter of this action and the Settlement Agreement for purposes of construing and enforcing the Settlement Agreement, including remedies for violation of said matters, and each party expressly reserves its rights to pursue the other party for violation of said matters.

Smith Deck Ex. A. ¶ 3. Upon entry of the Stipulation of Dismissal, the Pandora Litigation was closed, and the action remains closed to this day.

Meanwhile, on July 7, 2009, Medacist filed a separate Complaint against Omnicell in the Southern District of New York (the “Omni-cell Litigation”), also alleging infringement of the '736 Patent. Compl. ¶ 15. The Omnicell Litigation is currently pending. Compl. ¶ 16. Pandora is not a party to that ease.

Beginning sometime around October 2009, Medacist began to raise concerns that Pandora was in breach of certain royalty obligations under the settlement and license agreement. Medacist and Pandora engaged in some communications regarding the al[472]*472leged breach, and there is a dispute as to whether these communications and Pandora’s payment of certain disputed royalties resolved the issue. It appears that the parties had no further contact regarding the issue between March 2010 and October 2010.

On September 29, 2010, Omnicell and Pandora reached a confidential agreement regarding the terms of an acquisition of Pandora by Omnicell (the “Pandora Acquisition”). Compl. ¶ 17. On October 5, 2010, the acquisition was announced to the public, and the acquisition was completed through the sale of 100 percent of outstanding Pandora stock to Omnicell. Compl. ¶¶ 17-18. In light of this acquisition, Omnicell contends that, as 100 percent owner of voting stock in Pandora, it is now entitled to the benefit of the Pandora License. Compl. ¶ 19. On October 12, 2010, however, Medacist sent letters to counsel for Pandora and Omnicell alleging that the Pandora Acquisition constituted a breach of the Pandora License and that any assignment of the Pandora License to Omnicell would exceed the scope of the license agreement and would be challenged by Medacist. Compl. ¶¶ 20, 22. The letter sent to Pandora’s counsel demanded a meeting within 8 days and stated that if Medacist did not receive a response by October 15, 2010, it would pursue the rights and remedies available to it at law and under the Pandora License. Compl. ¶ 21.

On October 20, 2010, in response to the apparent threat of litigation by Medacist, Plaintiffs Pandora and Omnieell filed a Complaint for Declaratory Judgment in the Northern District of California. Plaintiffs seek a declaration that they have not substantially or materially breached the Pandora License, that Omnicell is entitled to the benefit of the License, and that any assignment of the License to Omnicell is valid and permissible under the terms of the License. Compl. ¶ 30. Plaintiffs also bring a claim against Medacist for breach of the duty of good faith and fair dealing. Compl. ¶¶ 32-39.

On November 12, 2010, Medacist filed a Motion to Open Judgment, to Enforce Settlement Agreement and License, and for Temporary and Permanent Restraints in the closed Pandora Litigation in the District of Connecticut. The District of Connecticut has not yet ruled on this motion, and the case currently remains closed. Medacist contends that because the District of Connecticut expressly retained jurisdiction over the original Pandora Litigation for purposes of construing and enforcing the settlement agreement, reopening the Pandora Litigation is the only proper means of resolving disputes regarding enforcement and interpretation of the settlement agreement and license. On this theory, Medacist now moves to dismiss this action, or, in the alternative, to transfer it to the District of Connecticut, on grounds of improper venue pursuant to Rule 12(b)(3) and 28 U.S.C. § 1406(a).

II. Discussion

A. Legal standard

Under Federal Rule of Civil Procedure 12(b)(3), a defendant may move to dismiss a complaint for improper venue. Generally, courts look to the venue provisions of 28 U.S.C. § 1391 to determine whether venue is proper. However, even if venue would otherwise be proper under 28 U.S.C. § 1391

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Ray v. Cuccinelli
N.D. California, 2020
Earth Island Institute v. Quinn
56 F. Supp. 3d 1110 (N.D. California, 2014)
Martensen v. Koch
942 F. Supp. 2d 983 (N.D. California, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
272 F.R.D. 469, 2011 U.S. Dist. LEXIS 13188, 2011 WL 588072, Counsel Stack Legal Research, https://law.counselstack.com/opinion/omnicell-inc-v-medacist-solutions-group-llc-cand-2011.